1. What Happened in H1 2025?
PharmaResearch reported revenue of ₩257.5 billion and operating profit of ₩100.6 billion, demonstrating a remarkable year-on-year growth of 63.3% and 75.2% respectively. Medical device sales reached ₩154.4 billion, driving overall growth. The successful market entry of ReenTox and steady sales of existing products like Rejuran and ConJuran were key factors in this improved performance.
2. Why This Success?
The successful launch of ReenTox has significantly boosted PharmaResearch’s toxin business expansion. Continuous R&D investment has secured new pipelines, raising expectations for future growth drivers. Efficient cost and SG&A management also contributed significantly to improved profitability.
3. What’s Next?
Analysts maintain a ‘Buy’ rating with a target price of ₩71,000 based on PharmaResearch’s positive fundamentals and growth potential. However, financial burdens related to convertible preferred stocks and bonds, exchange rate fluctuations, and subsidiary litigation risks require ongoing monitoring.
4. Investor Action Plan?
PharmaResearch is expected to offer attractive investment opportunities in the long term. However, investors should carefully consider potential risk factors before making investment decisions and align their investments with their investment objectives and risk tolerance.
Q. What were PharmaResearch’s key achievements in H1 2025?
A. They achieved remarkable growth with revenue of ₩257.5 billion (YoY +63.3%) and operating profit of ₩100.6 billion (YoY +75.2%). The successful market entry of ReenTox and growth in the medical device sector were particularly noteworthy.
Q. What are PharmaResearch’s main products?
A. Key products include Rejuran, ConJuran, and ReenTox.
Q. What should investors consider when investing in PharmaResearch?
A. Investors should consider financial burdens related to convertible preferred stocks and bonds, exchange rate volatility, and litigation risks associated with subsidiaries.
Leave a Reply